血浆糖化CD59预测早期妊娠期糖尿病及大于胎龄儿
在693名肥胖孕妇中评估血浆糖化CD59(pGCD59)对早期妊娠期糖尿病(GDM<20周)的识别能力及其与大于胎龄儿(LGA)的关联。pGCD59识别早期GDM的ROC曲线下面积为0.86(95%CI 0.83-0.90);母体pGCD59每升高1单位,分娩LGA儿的比值比为1.4(95%CI 1.1-1.8;P=0.016)。
要点
- pGCD59识别早期GDM的AUC为0.86(95%CI 0.83-0.90)。
- GDM<20周者平均pGCD59为3.9±1.1 SPU,无GDM者为2.7±0.7 SPU(P<0.001)。
- 母体pGCD59每升高1单位,分娩LGA儿的比值比为1.4(95%CI 1.1-1.8;P=0.016)。
核心结论
- pGCD59是检测早期妊娠期糖尿病和评估大于胎龄儿风险的简单且准确的生物标志物。
研究设计与样本
- 在维生素D与生活方式干预研究的693名肥胖(BMI>29)孕妇中,于妊娠<20周行75g、2小时口服葡萄糖耐量试验(OGTT)并检测血浆pGCD59水平。
- 主要分析纳入486名整个孕期糖耐量正常者、207名于<20周符合GDM标准者及77名于妊娠24至28周诊断为GDM者。
- 参考试验为75g、2小时OGTT,依据国际糖尿病与妊娠研究组协会标准判定;指标试验为pGCD59 ELISA。
主要发现
- GDM<20周组平均pGCD59水平为3.9±1.1标准肽单位(SPU),显著高于无GDM组的2.7±0.7 SPU(P<0.001)。
- pGCD59识别早期妊娠期糖尿病的ROC曲线下面积为0.86(95%CI 0.83-0.90)。
- 母体pGCD59水平每升高1单位,分娩LGA儿的比值比为1.4(LGA vs 非LGA;95%CI 1.1-1.8;P=0.016)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Gestational diabetes mellitus (GDM) diagnosed in early pregnancy is a health care challenge because it increases the risk of adverse outcomes. Plasma-glycated CD59 (pGCD59) is an emerging biomarker for diabetes and GDM. The aim of this study was to assess the performance of pGCD59 as a biomarker of early GDM and its association with delivering a large for gestational age (LGA) infant. OBJECTIVES: To assess the performance of pGCD59 to identify women with GDM in early pregnancy (GDM < 20) and assess the association of pGCD59 with LGA and potentially others adverse neonatal outcomes linked to GDM. METHODS: Blood levels of pGCD59 were measured in samples from 693 obese women (body mass index > 29) undergoing a 75-g, 2-hour oral glucose tolerance test (OGTT) at <20 weeks' gestation in the Vitamin D and Lifestyle Intervention study: the main analyses included 486 subjects who had normal glucose tolerance throughout the pregnancy, 207 who met criteria for GDM at <20 weeks, and 77 diagnosed with GDM at pregnancy weeks 24 through 28. Reference tests were 75-g, 2-hour OGTT adjudicated based on International Association of Diabetes and Pregnancy Study Group criteria. The index test was a pGCD59 ELISA. RESULTS: Mean pGCD59 levels were significantly higher (P < 0.001) in women with GDM < 20 (3.9 ± 1.1 standard peptide units [SPU]) than in those without (2.7 ± 0.7 SPU). pGCD59 accurately identified GDM in early pregnancy with an area under the curve receiver operating characteristic curves of 0.86 (95% confidence interval [CI], 0.83-0.90). One-unit increase in maternal pGCD59 level was associated with 36% increased odds of delivering an LGA infant (odds ratio for LGA vs non-LGA infant: 1.4; 95% CI, 1.1-1.8; P = 0.016). CONCLUSION: Our results indicate that pGCD59 is a simple and accurate biomarker for detection of GDM in early pregnancy and risk assessment of LGA.
引用
- Ma D, Luque-Fernandez MA, Bogdanet D, et al. Plasma Glycated CD59 Predicts Early Gestational Diabetes and Large for Gestational Age Newborns. J Clin Endocrinol Metab. 2020. PMID: 32069353. doi:10.1210/clinem/dgaa087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。